Article
Supporting Information Available: Experimental protocols
and analytical data for final compounds 2-17, 23-30, 33-37
and all intermediates, summary of crystallographic analysis of
compounds 2, 12, 14, 15, 17, 23, 35, and 36 (Table S1), and
description of PAMPA assay. This material is available free of
Journal of Medicinal Chemistry, 2010, Vol. 53, No. 21 7697
Fry, A. M. Identification by high-throughput screening of viridin
analogs as biochemical and cell-based inhibitors of the cell cycle-
regulated Nek2 kinase. J. Biomol. Screening 2010, 15, 918–927.
(21) Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful
metric for lead selection. Drug Discovery Today 2004, 9, 430–431.
(22) Martin, Y. C. A bioavailability score. J. Med. Chem. 2005, 48,
3164–3170.
(23) Richards, M. W.; O’Regan, L.; Mas-Droux, C.; Blot, J. M.;
Cheung, J.; Hoelder, S.; Fry, A. M.; Bayliss, R. An autoinhibitory
tyrosine motif in the cell-cycle-regulated Nek7 kinase is released
through binding of Nek9. Mol. Cell 2009, 36, 560–570.
(24) Hilton, S.; Naud, S.; Caldwell, J. J.; Boxall, K.; Burns, S.; Anderson,
V. E.; Antoni, L.; Allen, C. E.; Pearl, L. H.; Oliver, A. W.; Wynne
Aherne, G.; Garrett, M. D.; Collins, I. Identification and character-
isation of 2-aminopyridine inhibitors of checkpoint kinase 2. Bioorg.
Med. Chem. 2010, 18, 707–718.
(25) Zuccotto, F.; Ardini, E.; Casale, E; Angiolini, M. Through the
“gatekeeper door”: Exploiting the active kinase conformation.
J. Med. Chem. 2010, 53, 2681–2694.
(26) Westwood, I.; Cheary, D. M.; Baxter, J. E.; Richards, M. W.; van
Montfort, R. L.; Fry, A. M.; Bayliss, R. Insights into the con-
formational variability and regulation of human Nek2 kinase.
J. Mol. Biol. 2009, 386, 476–485.
(27) The sequence alignment containing 491 human ePK kinase domains,
rence and frequency of amino acids at specific positions within the
catalytic domain.
(28) Kothe, M.; Kohls, D.; Low, S.; Coli, R.; Rennie, G. R.; Feru, F.;
Kuhn, C.; Ding, Y. H. Selectivity-determining residues in Plk1.
Chem. Biol. Drug Des. 2007, 70, 540–546.
(29) Kothe, M.; Kohls, D.; Low, S.; Coli, R.; Cheng, A. C.; Jacques,
S. L.; Johnson, T. L.; Lewis, C.; Loh, C.; Nonomiya, J.; Sheils,
A. L.; Verdries, K. A.; Wynn, T. A.; Kuhn, C.; Ding, Y. H.
Structure of the catalytic domain of human polo-like kinase 1.
Biochemistry 2007, 46, 5960–5971.
(30) Kornev, A. P.; Haste, N. M.; Taylor, S. S.; Eyck, L. F. Surface
comparison of active and inactive protein kinases identifies a
conserved activation mechanism. Proc. Natl. Acad. Sci. U.S.A.
2006, 103, 17783–17788.
References
(1) O’Regan, L.; Blot, J.; Fry, A. M. Mitotic regulation by NIMA-
related kinases. Cell Div. 2007, 2, 25.
(2) Fry, A. M.; Meraldi, P.; Nigg, E. A. A centrosomal function for the
human Nek2 protein kinase, a member of the NIMA family of cell
cycle regulators. EMBO J. 1998, 17, 470–481.
(3) Fry, A. M.; Mayor, T.; Meraldi, P.; Stierhof, Y. D.; Tanaka, K.;
Nigg, E. A. C-Nap1, a novel centrosomal coiled-coil protein and
candidate substrate of the cell cycle-regulated protein kinase Nek2.
J. Cell Biol. 1998, 141, 1563–1574.
(4) Bahe, S.; Stierhof, Y. D.; Wilkinson, C. J.; Leiss, F.; Nigg, E. A.
Rootletin forms centriole-associated filaments and functions in
centrosome cohesion. J. Cell Biol. 2005, 171, 27–33.
(5) Rapley, J.; Baxter, J. E.; Blot, J.; Wattam, S. L.; Casenghi, M.;
Meraldi, P.; Nigg, E. A.; Fry, A. M. Coordinate regulation of the
mother centriole component Nlp by Nek2 and Plk1 protein
kinases. Mol. Cell. Biol. 2005, 25, 1309–1324.
(6) Di Agostino, S.; Fedele, M.; Chieffi, P.; Fusco, A.; Rossi, P.;
Geremia, R.; Sette, C. Phosphorylation of high-mobility group
protein A2 by Nek2 kinase during the first meiotic division in
mouse spermatocytes. Mol. Biol. Cell 2004, 15, 1224–1232.
(7) Chen, Y.; Riley, D. J.; Zheng, L.; Chen, P. L.; Lee, W. H.
Phosphorylation of the mitotic regulator protein Hec1 by Nek2
kinase is essential for faithful chromosome segregation. J. Biol.
Chem. 2002, 277, 49408–49416.
(8) Fry, A. M.; Schultz, S. J.; Bartek, J.; Nigg, E. A. Substrate
specificity and cell cycle regulation of the Nek2 protein kinase, a
potential human homolog of the mitotic regulator NIMA of
Aspergillus nidulans. J. Biol. Chem. 1995, 270, 12899–12905.
(9) Hames, R. S.; Wattam, S. L.; Yamano, H.; Bacchieri, R.; Fry,
A. M. APC/C-mediated destruction of the centrosomal kinase
Nek2A occurs in early mitosis and depends upon a cyclin A-type
D-box. EMBO J. 2001, 20, 7117–7127.
(10) Eto, M.; Elliott, E.; Prickett, T. D.; Brautigan, D. L. Inhibitor-2
regulates protein phosphatase-1 complexed with NimA-related
kinase to induce centrosome separation. J. Biol. Chem. 2002, 277,
44013–44020.
(31) Quarmby, L. M.; Mahjoub, M. R. Caught Nek-ing: cilia and
centrioles. J. Cell Sci. 2005, 118, 5161–5169.
(32) Polci, R.; Peng, A.; Chen, P. L.; Riley, D. J.; Chen, Y. NIMA-
related protein kinase 1 is involved early in the ionizing radiation-
induced DNA damage response. Cancer Res. 2004, 64, 8800–8803.
(33) Marshall, J. A.; Van Devender, E. A. Synthesis of (-)-deoxy-
pukalide, the enantiomer of a degradation product of the furano-
cembranolide pukalide. J. Org. Chem. 2001, 66, 8037–8041.
(34) Olofson, R. A.; Martz, J. T.; Senet, J.-P.; Piteau, M.; Malfroot, T.
A new reagent for the selective, high-yield N-dealkylation of
tertiary amines: improved syntheses of naltrexone and nalbuphine.
J. Org. Chem. 1984, 49, 2081–2082.
(11) Hayward, D. G.; Fry, A. M. Nek2 kinase in chromosome instabil-
ity and cancer. Cancer Lett. 2006, 237, 155–166.
(12) Faragher, A. J.; Fry, A. M. Nek2A kinase stimulates centrosome
disjunction and is required for formation of bipolar mitotic spin-
dles. Mol. Biol. Cell 2003, 14, 2876–2889.
(35) Snow, R. J.; Baker, R.; Herbert, R. H.; Hunt, I. J.; Merchant, K. J.;
Saunders, J. The synthesis of 5- and 6-substituted quinuclidine-
3-carboxylic esters: intermediates for novel muscarinic ligands.
J. Chem. Soc., Perkin Trans. 1 1991, 409–420.
(13) Hayward, D. G.; Clarke, R. B.; Faragher, A. J.; Pillai, M. R.;
Hagan, I. M.; Fry, A. M. The centrosomal kinase Nek2 displays
elevated levels of protein expression in human breast cancer.
Cancer Res. 2004, 64, 7370–7376.
(14) Fletcher, L.; Cerniglia, G. J.; Nigg, E. A.; Yend, T. J.; Muschel,
R. J. Inhibition of centrosome separation after DNA damage:
a role for Nek2. Radiat. Res. 2004, 162, 128–135.
(15) Kokuryo, T.; Senga, T.; Yokoyama, Y.; Nagino, M.; Nimura, Y.;
Hamaguchi, M. Nek2 as an effective target for inhibition of
tumorigenic growth and peritoneal dissemination of cholangiocar-
cinoma. Cancer Res. 2007, 67, 9637–9642.
(16) Tsunoda, N.; Kokuryo, T.; Oda, K.; Senga, T.; Yokoyama, Y.;
Nagino, M.; Nimura, Y.; Hamaguchi, M. Nek2 as a novel molec-
ular target for the treatment of breast carcinoma. Cancer Sci. 2009,
100, 111–116.
€
ꢀ
(36) Furstner, A.; Leitner, A.; Mendez, M.; Krause, H. Iron-catalyzed
cross-coupling reactions. J. Am. Chem. Soc. 2002, 124, 13856–13863.
(37) Hutchison, A. J.; Chenard, B. L.; Luke, G. P.; Li, G.; Ghosh, M.;
Peterson, J. M.; Tarrant, J. G.; Doller, D. Substituted 1-Hetero-
aryl-4-Substituted Piperazine and Piperidine Analogues. Patent
Application US2005/0239791, 2005.
(38) Rombouts, F. J. R.; De Borggraeve, W. M.; Delaere, D.; Froeyen,
M.; Toppet, S. M.; Compernolle, F.; Hoornaert, G. J. Develop-
ment of a functionalizable external β-turn mimic based on a
cis-fused 1,7-naphthyridine scaffold. Eur. J. Org. Chem. 2003,
1868–1878.
(17) Suzuki, K.; Kokuryo, T.; Senga, T.; Yokoyama, Y.; Nagino, M.;
Hamaguchi, M. Novel combination treatment for colorectal cancer
using Nek2 siRNA and cisplatin. Cancer Sci. 2010, 101, 1163–1169.
(18) Qiu, X. L.; Li, G.; Wu, G.; Zhu, J.; Zhou, L.; Chen, P. L.;
Chamberlin, A. R.; Lee, W. H. Synthesis and biological evaluation
of a series of novel inhibitor of Nek2/Hec1 analogues. J. Med.
Chem. 2009, 52, 1757–1767.
(19) Emmitte, K. A.; Adjabeng, G. M.; Andrews, C. W.; Alberti, J. G.;
Bambal, R.; Chamberlain, S. D.; Davis-Ward, R. G.; Dickson,
H. D.;Hassler, D. F.;Hornberger, K. R.;Jackson, J. R.;Kuntz, K. W.;
Lansing, T. J.; Mook, R. A., Jr.; Nailor, K. E.; Pobanz, M. A.; Smith,
S. C.; Sung, C. M.; Cheung, M. Design of potent thiophene inhibitors
of polo-like kinase 1 with improved solubility and reduced protein
binding. Bioorg. Med. Chem. Lett. 2009, 19, 1694–1697.
(39) Hartz, R. A.; Ahuja, V. T.; Arvanitis, A. G.; Rafalski, M.; Yue,
E. W.; Denhart, D. J.; Schmitz, W. D.; Ditta, J. L.; Deskus, J. A.;
Brenner, A. B.; Hobbs, F. W.; Payne, J.; Lelas, S.; Li, Y. W.;
Molski, T. F.; Mattson, G. K.; Peng, Y.; Wong, H.; Grace, J. E.;
Lentz, K. A.; Qian-Cutrone, J.; Zhuo, X. L.; Shu, Y. Z.; Lodge,
N. J.; Zaczek, R.; Combs, A. P.; Olson, R. E.; Bronson, J. J.;
Mattson, R. J.; Macor, J. E. Synthesis, structure-activity relation-
ships, and in vivo evaluation of N3-phenylpyrazinones as novel
corticotropin-releasing factor-1 (CRF1) receptor antagonists. J. Med.
Chem. 2009, 52, 4173–4191.
(40) Suginome, H.; Orito, K.; Yorita, K.; Ishikawa, M.; Shimoyama,
N.; Sasaki, T. Photoinduced molecular transformations. 157. A new
stereo- and regioselective synthesis of 2,6-diaryl-3,7-dioxabicyclo-
[3.3.0]octane lignans involving a β-scission of alkoxy1 radicals as
the key step. New total syntheses of (()-sesamin, (()-eudesmin, and
(()-yangambin. J. Org. Chem. 1995, 60, 3052–3064.
(20) Hayward, D. G.; Newbatt, Y.; Pickard, L.; Byrne, E.; Mao, G.;
Burns, S.; Sahota, N. K.; Workman, P.; Collins, I.; Aherne, W.;